Applied Therapeutics Q2 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate, Sales $144.000K May Not Be Comparable To $2.500M Estimate
Portfolio Pulse from Benzinga Newsdesk
Applied Therapeutics reported a Q2 2024 GAAP EPS of $(0.13), beating the estimate of $(0.15). Sales were $144.000K, which may not be comparable to the $2.500M estimate.
August 07, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Applied Therapeutics reported better-than-expected Q2 2024 GAAP EPS of $(0.13) compared to the $(0.15) estimate. However, sales figures of $144.000K may not be directly comparable to the $2.500M estimate.
The better-than-expected EPS is a positive indicator for the stock, likely leading to a short-term price increase. However, the sales figures' comparability issue introduces some uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100